Nebivolol is a third-generation β-adrenoceptor antagonist. It differs from other β-
adrenoceptor antagonists as it combines highly selective β 1-adrenoceptor antagonist …

Nebivolol is a third generation β-blocker. It is highly selective for the β1-adrenoceptor, and
has additional nitric oxide-mediated vasodilating and antioxidant properties, along with a …

Objective: TO describe the pharmacologic and pharmacokinetic properties of a new β-
adrenergic blocker, nebivolol, and review the literature evaluating its efficacy in the …

Nebivolol is a highly selective beta1-adrenergic blocker that also enhances nitric oxide
bioavailability via the L-arginine-nitric oxide pathway, leading to vasodilation and decreased …

Nebivolol is a β-blocker under US Food and Drug Administration review for the treatment of
hypertension. The unique pharmacologic properties of nebivolol include high specificity for …

Purpose. The pharmacology, pharmacokinetics, clinical efficacy, adverse effects, safety,
economic issues, dosage, and place in therapy of nebivolol are reviewed. Summary …

Abstract β-adrenergic blocking agents, a pharmacologically diverse class of cardiovascular
medications, are recommended as first-line treatment for patients with hypertension and …

Endothelial dysfunction is a systemic pathological state of the endothelium characterized by
a reduction in the bioavailability of vasodilators, essentially nitric oxide, leading to impaired …

Background: Nebivolol is a third-generation β1-selective β-blocker that is approved for the
treatment of hypertension. Objective: This article reviews the clinical pharmacology of …

Nebivolol is a highly selective β 1-adrenergic receptor antagonist with a pharmacologic
profile that differs from those of other drugs in its class. In addition to cardioselectivity …